• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

更正：靶向间皮素膜近端表位的经修饰嵌合抗原受体T细胞增强了对大型实体瘤的抗肿瘤功能。

Correction: Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.

作者信息

Zhang Zhiwei, Jiang Duqing, Yang Huan, He Zhou, Liu Xiangzhen, Qin Wenxia, Li Linfang, Wang Chao, Li Yang, Li He, Xu Hai, Jin Huajun, Qian Qijun

机构信息

Department of Biotherapy, The Eastern Hepatobiliary Surgery Hospital, Navy Medical University (Second Military Medical University), Shanghai, 201805, China.

Shanghai Engineering Research Center for Cell Therapy, Shanghai, 201805, China.

出版信息

Cell Death Dis. 2020 Apr 16;11(4):235. doi: 10.1038/s41419-020-2450-z.

DOI:10.1038/s41419-020-2450-z
PMID:32300103
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7162925/
Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

摘要

本文的一个修订版本已发表，可通过本文顶部的链接获取。

相似文献

1
Correction: Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.更正：靶向间皮素膜近端表位的经修饰嵌合抗原受体T细胞增强了对大型实体瘤的抗肿瘤功能。
Cell Death Dis. 2020 Apr 16;11(4):235. doi: 10.1038/s41419-020-2450-z.
2
Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.修饰后的嵌合抗原受体 T 细胞靶向间皮素膜近端表位，增强了对大实体瘤的抗肿瘤功能。
Cell Death Dis. 2019 Jun 17;10(7):476. doi: 10.1038/s41419-019-1711-1.
3
Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.靶向 TGF-β 的溶瘤腺病毒增强了针对乳腺癌的间皮素靶向嵌合抗原受体 T 细胞治疗的抗肿瘤反应。
Cell Immunol. 2020 Feb;348:104041. doi: 10.1016/j.cellimm.2020.104041. Epub 2020 Jan 11.
4
The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice.间皮素嵌合抗原受体T细胞（Mesothelin-CAR-T细胞）对小鼠实体瘤的抗肿瘤能力。
Mol Ther Oncolytics. 2021 Feb 24;20:556-568. doi: 10.1016/j.omto.2021.02.013. eCollection 2021 Mar 26.
5
Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.出版商更正：用于晚期甲状腺癌治疗的靶向ICAM-1的嵌合抗原受体T细胞的制造及临床前验证
Sci Rep. 2020 Jul 27;10(1):12733. doi: 10.1038/s41598-020-69586-8.
6
Author Correction: A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.作者更正：一种经修饰以表达成纤维细胞活化蛋白的全细胞肿瘤疫苗可诱导针对肿瘤细胞和癌症相关成纤维细胞的抗肿瘤免疫。
Sci Rep. 2020 Sep 21;10(1):15609. doi: 10.1038/s41598-020-72743-8.
7
Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells.靶向 A2a 受体的遗传和药理学方法可改善抗间皮素 CAR T 细胞的功能。
J Exp Clin Cancer Res. 2020 Mar 10;39(1):49. doi: 10.1186/s13046-020-01546-6.
8
Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.作者更正：具有完全人源化结合结构域的抗CD19嵌合抗原受体T细胞在B细胞淋巴瘤患者中的安全性和可行性。
Nat Med. 2020 May;26(5):803. doi: 10.1038/s41591-020-0864-x.
9
A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.一种新型 Siglec-4 衍生间隔物可改善 CAR T 细胞针对膜近端表位的功能。
Front Immunol. 2020 Aug 7;11:1704. doi: 10.3389/fimmu.2020.01704. eCollection 2020.
10
Author Correction: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.作者更正：针对登革病毒E二聚体表位的人源抗体对寨卡病毒感染具有治疗活性。
Nat Immunol. 2020 Mar;21(3):354. doi: 10.1038/s41590-019-0560-5.

引用本文的文献

1
Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and Challenges.用于治疗胆管癌的嵌合抗原受体T细胞疗法和个性化疫苗的发展：当前进展、作用机制及挑战
Am J Pathol. 2025 Mar;195(3):453-469. doi: 10.1016/j.ajpath.2024.10.021. Epub 2024 Dec 14.
2
Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas.肿瘤中持续存在激活的抗间皮素 hYP218 嵌合抗原受体 T 细胞与胃癌和结直肠癌的疗效相关。
Clin Transl Med. 2024 Nov;14(11):e70057. doi: 10.1002/ctm2.70057.
3
Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.开发高效的抗间皮素 hYP218 嵌合抗原受体 T 细胞，增强肿瘤浸润和持久性，用于治疗实体瘤。
Mol Cancer Ther. 2022 Jul 5;21(7):1195-1206. doi: 10.1158/1535-7163.MCT-22-0073.